US firm Akorn has signed a memorandum of understanding with Bioluz SA, a privately-held French company, for five pre-mix products. The estimated market size of these agents, based on recent IMS data, is about $175.0 million. Pre-mix medications are ready to use intravenous drug products that eliminate compounding steps in the pharmacy or at the point of care.
Under the terms of the accord, Akorn will be responsible for the development, regulatory filings, marketing and distribution of the pre-mix product line. Bioluz will exclusively manufacture the products at its intravenous solutions manufacturing facility and Akorn will own the Abbreviated New Drug Applications. Financial terms were not disclosed, but both parties expect to execute the definitive development and supply agreement within 60 days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze